Neurocrine Biosciences | NBIX - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.77B 132M 2025-09
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 10.58M 5.55M 2025-12
ALKERMES USD 334.02M 21.08M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
Amgen USD 9.57B 1.08B 2025-12
Biogen USD 1.85B 234M 2025-09
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Cytokinetics USD 1.81M 6.6M 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Exelixis USD 286.92M 24.38M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Incyte USD 1.02B 128.52M 2025-12
Ionis Pharmaceuticals USD 66M 41.39M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Pfizer USD 18.12B 2.02B 2025-09
Prothena USD 5.16M 0 2023-12
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Repligen USD 158.59M 9.62M 2025-12
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Teva Pharmaceutical Industries USD 3.71B 101M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12
Xoma USD 14.78M 4.96M 2024-06